MRGPRX2 and atopic eczema: Following successful basic in vivo studies in mouse and dog models [109], two clinical trials have been initiated with an orally administered specific MRGPRX2 antagonist—the synthetic small molecule compound EP262—in the indications of chronic spontaneous urticaria and atopic dermatitis [110].